Dipeptidylpeptidase IV inhibitors for use in the treatment of Type II diabetes

摘要

The present invention provides compositions comprising dipeptidylpeptidase IV inhibitor for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis.